Free Trial

Leerink Partnrs Has Pessimistic Outlook of REGN Q2 Earnings

Regeneron Pharmaceuticals logo with Medical background

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Analysts at Leerink Partnrs decreased their Q2 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research note issued to investors on Monday, July 7th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings per share of $6.97 for the quarter, down from their prior forecast of $7.71. The consensus estimate for Regeneron Pharmaceuticals' current full-year earnings is $35.92 per share.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. During the same period in the prior year, the company posted $9.55 earnings per share. The firm's quarterly revenue was down 3.7% on a year-over-year basis.

A number of other equities analysts have also weighed in on the stock. Robert W. Baird dropped their target price on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research report on Friday, April 25th. Argus downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Morgan Stanley reduced their target price on shares of Regeneron Pharmaceuticals from $755.00 to $754.00 and set an "overweight" rating on the stock in a research note on Thursday. UBS Group reduced their target price on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a research note on Thursday, June 5th. Finally, Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $822.54.

Get Our Latest Report on REGN

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded up $9.00 during mid-day trading on Wednesday, reaching $561.58. The stock had a trading volume of 388,905 shares, compared to its average volume of 1,136,208. The firm has a market cap of $60.63 billion, a price-to-earnings ratio of 14.30, a PEG ratio of 2.02 and a beta of 0.33. Regeneron Pharmaceuticals has a 12 month low of $476.49 and a 12 month high of $1,211.20. The business has a fifty day moving average of $546.58 and a 200 day moving average of $622.59. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.63%. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Brighton Jones LLC raised its holdings in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after buying an additional 686 shares during the period. Proficio Capital Partners LLC raised its holdings in Regeneron Pharmaceuticals by 30.5% in the 4th quarter. Proficio Capital Partners LLC now owns 308 shares of the biopharmaceutical company's stock valued at $219,000 after buying an additional 72 shares during the period. Raymond James Financial Inc. purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at about $65,180,000. Larson Financial Group LLC raised its holdings in Regeneron Pharmaceuticals by 62.0% in the 4th quarter. Larson Financial Group LLC now owns 81 shares of the biopharmaceutical company's stock valued at $58,000 after buying an additional 31 shares during the period. Finally, OFI Invest Asset Management purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at about $28,000. Institutional investors and hedge funds own 83.31% of the company's stock.

About Regeneron Pharmaceuticals

(Get Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

See Also

Earnings History and Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)

Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?

Before you consider Regeneron Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.

While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines